ArticleJournal of thoracic disease2026
Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation plays a pivotal role in tumor progression and patient prognosis in non-small cell lung cancer (NSCLC). While preoperative inflammatory biomarkers have demonstrated prognostic utility, the additional value of perioperative dynamic changes remains insufficiently characterized. This study aimed to evaluate the prognostic significance of both preoperative inflammatory biomarkers and their perioperative alterations in patients undergoing curative-intent surgical resection for NSCLC. Methods: We conducted a retrospective cohort study of 368 consecutive patients who underwent surgical resection for pathologically confirmed NSCLC at our institution between January 2022 and December 2024. Preoperative blood samples were analyzed for complete blood count, C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6). Inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) were calculated. Perioperative changes (Δ) were determined from postoperative day 1 values. Primary endpoints were disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) at 12 months. Kaplan-Meier analysis with log-rank tests and Cox proportional hazards regression were employed for survival analysis. Results: The median follow-up was 12.0 months. At 12 months, the DFS, RFS, and OS rates were 48.4%, 63.9%, and 75.0%, respectively. In univariate analysis, elevated NLR [≥2.78; hazard ratio (HR) =1.97, 95% confidence interval (CI): 1.48-2.62, P<0.001], elevated SII (≥585; HR =1.81, 95% CI: 1.35-2.42, P<0.001), low PNI (<47.8; HR =1.70, 95% CI: 1.28-2.27, P<0.001), elevated IL-6 (≥9.8 pg/mL; HR =1.71, 95% CI: 1.19-2.46, P=0.004), and high ΔNLR (≥7.8; HR =2.07, 95% CI: 1.50-2.85, P<0.001) were significantly associated with inferior DFS. Multivariate analysis identified advanced stage (IIB-IIIA; HR =1.41, 95% CI: 1.02-1.95, P=0.04), low PNI (HR =1.62, 95% CI: 1.21-2.17, P=0.001), elevated IL-6 (HR =1.67, 95% CI: 1.15-2.41, P=0.007), and high ΔNLR (HR =1.69, 95% CI: 1.15-2.50, P=0.008) as independent prognostic factors for DFS. The combined inflammatory index achieved superior discriminatory performance [area under the curve (AUC) =0.712] compared with individual markers. Conclusions: Perioperative inflammatory biomarkers, particularly the combination of preoperative PNI, IL-6, and perioperative ΔNLR, provide robust prognostic stratification in surgically resected NSCLC. Integration of these readily accessible biomarkers into clinical decision-making may facilitate personalized surveillance strategies and adjuvant therapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.